BOSTON SCIENTIFIC CORPORATION Increase (Decrease) in Accounts Payable and Accrued Liabilities
BOSTON SCIENTIFIC CORPORATION (BSX) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$278.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-03
- BOSTON SCIENTIFIC CORPORATION increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $234.00M, a 1.30% increase year-over-year.
- BOSTON SCIENTIFIC CORPORATION increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$512.00M.
- BOSTON SCIENTIFIC CORPORATION increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $285.00M, a 25.97% decline year-over-year.
- BOSTON SCIENTIFIC CORPORATION increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $165.00M, a 30.38% decline year-over-year.
- BOSTON SCIENTIFIC CORPORATION increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $296.00M, a 21.81% increase from fiscal 2024.
- BOSTON SCIENTIFIC CORPORATION increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $243.00M, a 105.93% increase from fiscal 2023.
- BOSTON SCIENTIFIC CORPORATION increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $118.00M.
- BOSTON SCIENTIFIC CORPORATION increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was -$255.00M, a 162.50% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $234.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$278.00M 10-Q · filed 2026-08-03 | $7.00M derived: sum of 3 quarters · filed 2026-08-03 | $172.00M derived: sum of 4 quarters · filed 2026-08-03 | |||
| 2026-03-31 | -$512.00M 10-Q · filed 2026-05-01 | -$227.00M derived: sum of 2 quarters · filed 2026-05-01 | -$62.00M derived: sum of 3 quarters · filed 2026-05-01 | $169.00M derived: sum of 4 quarters · filed 2026-08-03 | |||
| 2025-12-31 | $285.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $450.00M derived: sum of 2 quarters · filed 2026-02-17 | $681.00M derived: sum of 3 quarters · filed 2026-08-03 | $296.00M 10-K · filed 2026-02-17 | |||
| 2025-09-30 | $165.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $396.00M derived: sum of 2 quarters · filed 2026-08-03 | $11.00M 10-Q · filed 2025-11-03 | $396.00M derived: sum of 4 quarters · filed 2026-08-03 | |||
| 2025-06-30 | $231.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$154.00M 10-Q · filed 2026-08-03 | $231.00M derived: sum of 3 quarters · filed 2026-08-03 | $468.00M derived: sum of 4 quarters · filed 2026-08-03 | |||
| 2025-03-31 | -$385.00M 10-Q · filed 2026-05-01 | $0.00 derived: sum of 2 quarters · filed 2026-05-01 | $237.00M derived: sum of 3 quarters · filed 2026-05-01 | $308.00M derived: sum of 4 quarters · filed 2026-05-01 | |||
| 2024-12-31 | $385.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $622.00M derived: sum of 2 quarters · filed 2026-02-17 | $693.00M derived: sum of 3 quarters · filed 2026-02-17 | $243.00M 10-K · filed 2026-02-17 | |||
| 2024-09-30 | $237.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $308.00M derived: sum of 2 quarters · filed 2025-11-03 | -$142.00M 10-Q · filed 2025-11-03 | -$119.00M derived: sum of 4 quarters · filed 2026-02-17 | |||
| 2024-06-30 | $71.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-01 | -$379.00M 10-Q · filed 2025-08-01 | -$356.00M derived: sum of 3 quarters · filed 2026-02-17 | -$339.00M derived: sum of 4 quarters · filed 2026-02-17 | |||
| 2024-03-31 | -$450.00M 10-Q · filed 2025-05-01 | -$427.00M derived: sum of 2 quarters · filed 2026-02-17 | -$410.00M derived: sum of 3 quarters · filed 2026-02-17 | -$121.00M derived: sum of 4 quarters · filed 2026-02-17 | |||
| 2023-12-31 | $23.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $40.00M derived: sum of 2 quarters · filed 2026-02-17 | $329.00M derived: sum of 3 quarters · filed 2026-02-17 | $118.00M 10-K · filed 2026-02-17 | |||
| 2023-09-30 | $17.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-01 | $306.00M derived: sum of 2 quarters · filed 2024-11-01 | $95.00M 10-Q · filed 2024-11-01 | $430.00M derived: sum of 4 quarters · filed 2025-02-18 | |||
| 2023-06-30 | $289.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $78.00M 10-Q · filed 2024-08-01 | $413.00M derived: sum of 3 quarters · filed 2025-02-18 | $272.00M derived: sum of 4 quarters · filed 2025-02-18 | |||
| 2023-03-31 | -$211.00M 10-Q · filed 2024-05-01 | $124.00M derived: sum of 2 quarters · filed 2025-02-18 | -$17.00M derived: sum of 3 quarters · filed 2025-02-18 | -$98.00M derived: sum of 4 quarters · filed 2025-02-18 | |||
| 2022-12-31 | $335.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $194.00M derived: sum of 2 quarters · filed 2025-02-18 | $113.00M derived: sum of 3 quarters · filed 2025-02-18 | -$255.00M 10-K · filed 2025-02-18 | |||
| 2022-09-30 | -$141.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | -$222.00M derived: sum of 2 quarters · filed 2023-11-01 | -$590.00M 10-Q · filed 2023-11-01 | -$457.00M derived: sum of 4 quarters · filed 2024-02-20 | |||
| 2022-06-30 | -$81.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$449.00M 10-Q · filed 2023-08-03 | -$316.00M derived: sum of 3 quarters · filed 2024-02-20 | -$381.00M derived: sum of 4 quarters · filed 2024-02-20 | |||
| 2022-03-31 | -$368.00M 10-Q · filed 2023-05-04 | -$235.00M derived: sum of 2 quarters · filed 2024-02-20 | -$300.00M derived: sum of 3 quarters · filed 2024-02-20 | $33.00M derived: sum of 4 quarters · filed 2024-02-20 | |||
| 2021-12-31 | $133.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $68.00M derived: sum of 2 quarters · filed 2024-02-20 | $401.00M derived: sum of 3 quarters · filed 2024-02-20 | $408.00M 10-K · filed 2024-02-20 | |||
| 2021-09-30 | -$65.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $268.00M derived: sum of 2 quarters · filed 2022-11-03 | $275.00M 10-Q · filed 2022-11-03 | $611.00M derived: sum of 4 quarters · filed 2023-02-23 | |||
| 2021-06-30 | $333.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $340.00M 10-Q · filed 2022-08-04 | $187.00M 10-Q · filed 2021-08-06 | $676.00M derived: sum of 3 quarters · filed 2023-02-23 | $843.00M derived: sum of 4 quarters · filed 2023-02-23 | ||
| 2021-03-31 | $7.00M 10-Q · filed 2022-05-05 | -$10.00M 10-Q · filed 2021-05-06 | $343.00M derived: sum of 2 quarters · filed 2023-02-23 | $510.00M derived: sum of 3 quarters · filed 2023-02-23 | $435.00M derived: sum of 4 quarters · filed 2023-02-23 | ||
| 2020-12-31 | $336.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $503.00M derived: sum of 2 quarters · filed 2023-02-23 | $428.00M derived: sum of 3 quarters · filed 2023-02-23 | -$28.00M 10-K · filed 2023-02-23 | $88.00M 10-K · filed 2021-02-23 | ||
| 2020-09-30 | $167.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $92.00M derived: sum of 2 quarters · filed 2021-11-04 | -$364.00M 10-Q · filed 2021-11-04 | ||||
| 2020-06-30 | -$75.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | -$531.00M 10-Q · filed 2021-08-06 | |||||
| 2020-03-31 | -$456.00M 10-Q · filed 2021-05-06 | ||||||
| 2019-12-31 | $79.00M 10-K · filed 2022-02-23 | $111.00M 10-K · filed 2020-02-25 | |||||
| 2018-12-31 | -$640.00M 10-K · filed 2021-02-23 | -$631.00M 10-K · filed 2019-02-19 | |||||
| 2017-12-31 | $195.00M 10-K · filed 2020-02-25 | ||||||
| 2016-12-31 | $553.00M 10-K · filed 2019-02-19 | ||||||
| 2015-12-31 | -$20.00M 10-K · filed 2018-02-20 | ||||||
| 2014-12-31 | $620.00M 10-K · filed 2017-02-23 | ||||||
| 2013-12-31 | -$9.00M 10-K · filed 2016-02-24 | -$37.00M 10-K · filed 2014-02-26 | |||||
| 2012-12-31 | -$111.00M 10-K · filed 2015-02-25 | -$131.00M 10-K · filed 2013-02-22 | |||||
| 2011-12-31 | -$271.00M 10-K · filed 2014-02-26 | ||||||
| 2010-12-31 | -$1.15B 8-K · filed 2013-05-29 | ||||||
| 2009-12-31 | $462.00M 10-K · filed 2012-02-17 | ||||||
| 2008-12-31 | $392.00M 10-K · filed 2011-02-17 | ||||||
| 2007-12-31 | $45.00M 10-K · filed 2010-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BECTON DICKINSON & CO (BDX) | United States | $48.834B | 43.79 |
| 3M CO (MMM) | United States | $86.404B | 27.87 |
| DEXCOM INC (DXCM) | United States | $33.004B | 25.42 |
| WEST PHARMACEUTICAL SERVICES INC (WST) | United States | $26.288B | 43.14 |
| STRYKER CORP (SYK) | United States | $103.511B | 32.39 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |